Aspira Pathlab & Diagnostics (BOM:540788) ROCE %: -15.40% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540788 Aspira Pathlab & Diagnostics Ltd BOM:540788
51 GF Score
Price ₹106.90
GF Value ₹70.73
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Aspira Pathlab & Diagnostics ROCE %?

Aspira Pathlab & Diagnostics BOM:540788 -1.97% 51 ROCE % is -15.40% as of Mar. 2026. GuruFocus rates BOM:540788 with a GF Score™ of 51/100 and a GF Value™ of ₹70.73 (Significantly Overvalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aspira Pathlab & Diagnostics's annualized ROCE % for the quarter that ended in Mar. 2026 was -15.40%.

Aspira Pathlab & Diagnostics  (BOM:540788) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aspira Pathlab & Diagnostics ROCE % Related Terms

Aspira Pathlab & Diagnostics ROCE % Historical Data

* Premium members only.

The historical data trend for Aspira Pathlab & Diagnostics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspira Pathlab & Diagnostics ROCE % Chart

Aspira Pathlab & Diagnostics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.52 1.73 -16.59 17.46 2.90

Aspira Pathlab & Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.64 13.67 44.68 -33.82 -15.40
BOM:540788
51GF Score
Aspira Pathlab & Diagnostics Ltd BOM:540788
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aspira Pathlab & Diagnostics ROCE % Calculation

Aspira Pathlab & Diagnostics's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=4.407/( ( (174.615 - 23.724) + (185.057 - 31.958) )/ 2 )
=4.407/( (150.891+153.099)/ 2 )
=4.407/151.995
=2.90 %

Aspira Pathlab & Diagnostics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-23.576/( ( (0 - 0) + (185.057 - 31.958) )/ 1 )
=-23.576/( ( 0 + 153.099 )/ 1 )
=-23.576/153.099
=-15.40 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -15.40% mean?
Aspira Pathlab & Diagnostics (BOM:540788) has a ROCE % of -15.40% as of Mar. 2026.
Is Aspira Pathlab & Diagnostics' ROCE % too high?
Aspira Pathlab & Diagnostics' current ROCE % is -15.40%. Overall, Aspira Pathlab & Diagnostics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Pathlab & Diagnostics' ROCE % compare to TMO and DHR?
Aspira Pathlab & Diagnostics' ROCE % of -15.40% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Aspira Pathlab & Diagnostics's current ROCE % is -15.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Pathlab & Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics (BOM:540788) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹70.73, compared to a current price of ₹106.90 — trading 51.1% above its estimated fair value. The current ROCE % is -15.40%. Aspira Pathlab & Diagnostics' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Aspira Pathlab & Diagnostics (BOM:540788), the current ROCE % is -15.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspira Pathlab & Diagnostics (BOM:540788) Overvalued in 2026?

Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics stock appears to be overvalued. The current stock price of ₹106.90 is trading 51.1% above its estimated GF Value™ of ₹70.73. GuruFocus considers Aspira Pathlab & Diagnostics to be Significantly Overvalued.

Key valuation signals for BOM:540788:

  • ROCE %: -15.40%
  • GF Value™: ₹70.73 vs. price of ₹106.90 (51.1% above fair value)
  • GF Score™: 51/100 with 1 warning sign

No single metric tells the full story. See the BOM:540788 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspira Pathlab & Diagnostics Business Description

Address 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (west), Mumbai, MH, IND, 400086
Aspira Pathlab & Diagnostics Ltd is mainly engaged in pathology and related healthcare services. It operates laboratories that conduct a wide range of pathological investigations across branches such as biochemistry, hematology, histopathology, microbiology, immunochemistry, immunology, virology, cytology, and other pathological and radiological tests. The services offered include pathology tests, sonography, X-rays, and radiology. The company also provides various health packages like gynecology profiles, anemia profiles, monsoon profiles, coagulation tests, cancer screening packages, newborn screening and IEM panels, orthopedic profiles, allergy panels, and cardiac profiles. These comprehensive diagnostic services assist in disease diagnosis.
51GF Score

Get the complete analysis for BOM:540788

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹106.90
Price
₹70.73
GF Value